Abstract: Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Abstract: The present invention encompasses ATR inhibitor for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.

Abstract: Ophthalmic formulations for treatment of night vision disturbance syndrome (NVD) are presented and preferably comprise brimonidine, rivastigmine, and/or galantamine at very low concentrations. Such formulations unexpectedly provided acute and transient therapeutic effect to alleviate one or more symptoms associated with NVD.

Abstract: Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.

Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The invention comprises a shampoo apparatus and method of use thereof, comprising: (1) a pressurized container, a pressure in the container in a range of seventy to two hundred pounds per square inch and (2) a shampoo in the container, the shampoo comprising greater than five thousand parts per million carbon dioxide, where the shampoo optionally contains a detergent, zinc pyrrolidone carboxylic acid, and/or minoxidil. The carbon dioxide in the container is optionally added as a solid or a liquid and/or is chemically formed inside the container, such as from any of a carbonic acid, a bicarbonate, a bicarbonate salt, and/or a carbonate. The carbon dioxide solvates/makes soluble and aids removal of sebacic acid on the scalp.

Abstract: Provided herein are methods and compositions for diagnosing, treating, or ameliorating symptoms of cancer, including melanoma, with inhibitors of PRMTS and immune response regulators in combination with checkpoint inhibitor therapy.

Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase in a shortened infusion period less than 120 minutes and a shortened infusion volume of less than 250 mL. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

Abstract: Neurological disorders involving loss of neurons had been though incurable since the neurons are not regenerate in adults. Disclosed is a combination treatment of MS-818 and phenserine increased neurogenesis under AD pathological conditions. However, any brain damage, including stroke, Alzheimer's disease, ALS, MS, Parkinson's disease, traumatic brain injury, and even aging, is known to increase inflammatory signals (e.g., cytokines). We found those inflammatory signaling increased glial differentiation NSCs. Disclosed is a combination use of MS-818 and non-steroidal anti-inflammatory drug (NSAID) suppress inflammatory signaling increase neurogenesis, indicating this combination of the drugs could be useful as a therapy for any kind of neuronal damages.

Abstract: The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

Abstract: Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis.

Abstract: The application relates to methods for treating a viral infection, such as COVID-19 infection, comprising administering to the subject an inhibitor of S-adenosylhomocysteine (SAH) hydrolase.

Abstract: The present disclosure provides an active pharmaceutical ingredient containing a crystal form including a compound of Formula (I) and fumaric acid. An X-ray powder diffraction pattern of the crystal form obtained by using Cu-K? radiation includes at least three peaks selected from the group consisting of 10.94°±0.2° 2?, 19.06°±0.2° 2?, 23.50°±0.2° 2?, and 24.66°±0.2° 2?; a particle size D90 of the active pharmaceutical ingredient is smaller than or equal to 20 ?m, and a particle size D50 of the active pharmaceutical ingredient is smaller than or equal to 10 ?m.

Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Abstract: The present invention provides compositions, systems, kits, and methods for treating a subject, having a condition that causes a cytokine storm, by administering or providing a composition comprising a beta-secretase 1 (BACE1) inhibitor. In some embodiments, the composition reduces lung or other bodily inflammation in the subject (e.g., by reducing the cytokine storm caused by a virus). In certain embodiments, the subject is infected with a virus such as SARS-CoV-2, has received CAR-T cell immunotherapy, has an organ transplant, or has an autoimmune disease (e.g., arthritis).

Abstract: The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating thrombocythemia.

Abstract: Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70 - 140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ? 23 and/or a CDR-SOB score of ? 4.5.

Abstract: Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Abstract: A method for treating cognitive dysfunction by administering a therapeutically effective amount of a calcium channel stabilizer to a subject in need thereof. The preferred calcium channel stabilizers include a 1,4-benzothiazepine moiety, including those of the general structural formula: The method is useful with various types of respiratory viruses, including for coronaviruses, COVID, SARS and MERS. The method of treatment increases RyR2-Castabin2 binding in cardiac muscle of the subject while also decreasing open probability (Po) of RyR2 protein in the subject. All of these effects act to at least partially offset cognitive dysfunctions such as a deficit in attention, executive functioning, language, processing speed, memory, and combinations thereof.

Abstract: Disclosed herein are methods of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of (i) a glucocorticoid receptor (GR) antagonist and (ii) an androgen receptor (AR) degrader.

Abstract: Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.

Abstract: The present disclosure provides aqueous formulations comprising hydrocortisone sodium phosphate and monothioglycerol. In some embodiments, the formulations comprise monobasic sodium phosphate, dibasic sodium phosphate, or disodium EDTA. The present disclosure further provides a method of treating a disease or disorder in a subject by administering the aqueous formulation.

Abstract: The present disclosure relates to inotodiol as a liver X receptor agonist and use thereof for the treatment of a liver X receptor-mediated disease. Inotodiol according to an aspect, or a prodrug thereof has LXR?-specific agonist activity, and thus not only has remarkable safety compared to other LXR agonists, but can also be effectively used in the treatment of LXR-related diseases, such as a neurodegenerative brain disease, an autoimmune disease, NASH, and NAFLD.

Abstract: A method of treating reduced pulmonary function by administering an effective dose of a Farnesoid X Receptor (FXR) agonist, particularly obeticholic acid, is disclosed. Also disclosed is an in vivo animal model of lung injury and altered functioning, useful for identifying compounds active in restoring pulmonary function.

Abstract: Disclosed is compound YM155, tanshinone I or cryptotanshinone, or a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, or a crystal form thereof; for treating and/or preventing diseases caused by coronavirus.

Abstract: Compositions and methods of treatment involving transpore delivery of an active ingredient are provided.

Abstract: This present disclosure teaches a method for treating or delaying castration-resistant prostate cancer (CRPC) comprising co-administering to a subject in need of relief from said cancer a therapeutically effective amount of a sterol-O-acyltransferase 1 (SOAT1) inhibitor together with a therapeutically effective amount of one or more androgen receptor inhibitors/antagonists. Examples of inhibitor/antagonist of androgen receptor and androgen biosynthesis include enzalutamide and abiraterone; and examples of SOAT1 inhibitors include avasimibe. Pharmaceutical compositions and methods of uses for the treatment of CRPCs are within the scope of this disclosure.

Abstract: The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin D compound in a topical formulation. The invention has broad applications in chemotherapies that induce alopecia, for example taxane based chemotherapy for cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, soft tissue sarcoma, or bone sarcoma. The pharmaceutical compositions of the invention can be advantageously administered before and/or concurrent with the chemotherapy.

Abstract: A skin care composition includes an anti-acne active ingredient such as a sulfur ingredient, salicylic acid, or combinations thereof. The skin care composition further includes an odor neutralizer, an alpha hydroxy acid, or combinations thereof. In one example, the anti-acne active ingredient includes sulfur and the odor neutralizer includes a polymer to reduce and/or eliminate the odor caused by the sulfur. Additionally or alternatively, the alpha hydroxy acid includes a mixture comprising lactic acid, glycolic acid, malic acid, mandelic acid, tartaric acid, and citric acid to provide skin care benefits such as exfoliation with improved moisturization. A method to treat and/or prevent acne may include applying to facial skin one or more of a cleansing skin care composition, a treatment skin care composition, or a moisturizing skin care composition to minimize acne, irritation, dryness, odor, and the like.

Abstract: This invention relates to solid oral dosage forms of the HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof.

Abstract: The present disclosure provides a method for preventing and/or treating a damage to micro vascular integrity comprising administering to a subject, a composition comprising selected cannabinoid, thereby maintaining the microvascular integrity.

Abstract: A composition and corresponding method for immunomodulation. The composition includes an emulsion formed from a pharmaceutically acceptable carrier mixed with active ingredients. The pharmaceutically acceptable carrier is between 15-85 wt % of the composition. The active ingredients include an effective amount of a hemp extract to provide a source of exogenous cannabinoids, an effective amount of a cannabinoid enhancer to inhibit cannabinoid hydrolases, an effective amount of a fatty acid amide to enhance cannabinoid activity via an entourage effect, an effective amount of a kava extract to alleviate anxiety, and an effective amount of an alkaloid to enhance bioavailability of one or more of the active ingredients.

Abstract: Traditional methods of hash production are very labor intensive, and do not yield a product that is homogeneous, whether within a unit or across multiple units from a batch. The present disclosure relates to a hash product comprising a cohesive mass of isolated cannabis trichomes and a marker, where the distribution of the marker is substantially homogeneous throughout the product. For example, the detectable marker can be distributed in at least 80 vol.% of the hashish product. Additionally, or alternatively, the hashish product includes a first content of the marker in a core portion thereof and a second content of the marker in a peripheral portion thereof, where the first content and the second content are present in a ratio first content / second content of from 0.85 to 1.15. Such hash product may be consumed by inhalation or ingestion.

Abstract: Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

Abstract: Various embodiments of a gut microbiome modulating composition comprises a blend of a polyphenol and an oligosaccharide. Various embodiments of the polyphenol may comprise at least approximately 5% by weight chlorogenic acid. Various embodiments of the oligosaccharides may be standardized to a degree of polymerization of at least three to reduce digestibility. Administration of an effective amount of the gut microbiome modulating composition to a person or animal may stimulate the growth of at least one of Akkermansia muciniphila, Lactobacillus, and Bifidobacterium bacteria in the colon, which may reduce permeability of the colon, increases short chain fatty acid production in the colon, and/or modulate causes immunomodulation of human colon cells. The gut microbiome modulating composition may provide protective effects against obesity-related chronic diseases.

Abstract: Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.

Abstract: The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.

Abstract: Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of at least one glycopeptide antibiotic, at least one aminoglycoside antibiotic, and at least one amino acid. Methods for fabricating the compositions and using them are also described.

Abstract: The present application relates to formulations comprising a combination of an NAD+ agonist and a flavonoid polyphenol. Also provided herein are methods of administering a combination of an NAD+ agonist and a flavonoid for use in methods for treating, ameliorating, or preventing at least one symptom or indication an age-related disease or disorder in a subject.

Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.

Abstract: Methods for predicting response to immunotherapy and selecting immunotherapy for treating cancer, e.g., cancer of epithelial origin, in a subject.

Abstract: The present disclosure relates compositions and methods to treat neuromuscular diseases and disorders, e.g., spinal muscular atrophy (SMA), characterized by the presence of a splicing silencer located in SMN2 intron 7 pre-mRNA, comprising coadministering a therapeutically effective amount of an antisense oligonucleotide (ASO) complementary to a nucleotide sequence within intron 7 of human SMN2 pre-mRNA; and a subclinical dose of a histone deacetylate inhibitor, e.g., valproic acid, trichostatin A, or a combination thereof.

Abstract: In various aspects and embodiments the invention provides compositions and methods useful in the treatment of inflammatory disease, in particular, multiple sclerosis.

Abstract: RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.

Abstract: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.

Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

Abstract: Disclosed is a method for increased target specificity of a mannosylated carbohydrate polymeric therapeutic and/or diagnostic compound by administering a blocking composition comprising a backbone and one or more C-type lectin receptor targeting moieties attached thereto with an effective amount of the mannosylated dextran therapeutic and/or diagnostic compound. The administration of the blocking compound results in higher localization of the mannosylated dextran therapeutic and/or diagnostic compounds to a desired target other than the liver and/or spleen compared to without the administration of the blocking compound. The molecular weight of the blocking composition backbone is between about 1 kDa and about 35 kDa.

Abstract: Disclosed herein are methods for preventing or reducing the risk of developing, and/or preventing or reducing the risk of an increase in an amount of and/or a size of, and/or changing the shape of, circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of preventing or reducing the risk of cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.